Association of tumour necrosis factor alpha and its rece phosphorylase expression in invasive breast carcinoma

British Journal of Cancer 77, 2246-2251

DOI: 10.1038/bjc.1998.373

Citation Report

#	Article	IF	CITATIONS
1	Clinical significance of angiogenic factors in breast cancer. Breast Cancer Research and Treatment, 1998, 52, 159-173.	1.1	55
2	Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. British Journal of Cancer, 1999, 79, 991-995.	2.9	399
3	Combined role of tumor angiogenesis, bcl-2, and p53 expression in the prognosis of patients with colorectal carcinoma., 1999, 86, 1421-1430.		80
4	Thymidine phosphorylase: its role in sensitivity and resistance to anticancer drugs. Drug Resistance Updates, 1999, 2, 205-214.	6.5	45
5	The role of thymidine phosphorylase expression in the invasiveness of gastric carcinoma., 2000, 88, 2220-2227.		43
6	Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer. , 2000, 190, 430-436.		268
7	Co-expression of Thymidine Phosphorylase and Heme Oxygenase-1 in Macrophages in Human Malignant Vertical Growth Melanomas. Japanese Journal of Cancer Research, 2000, 91, 906-910.	1.7	76
8	Variations in the expression of platelet-derived endothelial cell growth factor in human colorectal polyps. Surgery Today, 2000, 30, 711-717.	0.7	7
9	Thymidine phosphorylase expression correlates with tumor differentiation and bcl-2 in invasive breast cancer. Breast Cancer, 2000, 7, 210-214.	1.3	4
10	Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood, 2000, 96, 2240-2245.	0.6	640
11	Tumour necrosis factor- \hat{l}_{\pm} and transforming growth factor- \hat{l}^2 are significantly associated with better prognosis in non-small cell lung carcinoma: putative relation with BCL-2-mediated neovascularization. British Journal of Cancer, 2000, 83, 480-486.	2.9	46
12	Auf der Spur eines RÃtsels: Angiogenese und Endometriose. Geburtshilfe Und Frauenheilkunde, 2000, 60, 585-593.	0.8	1
13	New paradigms for the treatment of cancer: The role of anti-angiogenesis agents. Advances in Cancer Research, 2000, 79, 1-38.	1.9	164
14	Immunomodulation therapy in colorectal carcinoma. Cancer Treatment Reviews, 2000, 26, 169-190.	3.4	20
15	A Potential Role for Interleukin-8 in the Metastatic Phenotype of Breast Carcinoma Cells. American Journal of Pathology, 2001, 158, 639-646.	1.9	156
16	Inflammation and cancer: back to Virchow?. Lancet, The, 2001, 357, 539-545.	6.3	6,677
17	Angiogenic effect of thymidine phosphorylase on macrophages in glioblastoma multiforme. Journal of Neurosurgery, 2001, 95, 89-95.	0.9	29
18	The angiogenic pathway ?vascular endothelial growth factor/flk-1(KDR)-receptor? in rheumatoid arthritis and osteoarthritis. Journal of Pathology, 2001, 194, 101-108.	2.1	87

#	Article	IF	Citations
19	Host microenvironment in breast cancer development: Inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumor–microenvironment interactions. Breast Cancer Research, 2002, 5, 31-6.	2.2	235
20	Thymidine phosphorylase expression in tumor-infiltrating macrophages may be correlated with poor prognosis in uterine endometrial cancer. Human Pathology, 2002, 33, 1105-1113.	1.1	32
21	Tumor necrosis factor or tumor promoting factor?. Cytokine and Growth Factor Reviews, 2002, 13, 135-141.	3.2	469
22	Hypoxia-induced pathways in breast cancer. Microscopy Research and Technique, 2002, 59, 41-48.	1.2	57
23	Possible co-regulation of genes associated with enhanced progression of mammary adenocarcinomas. Immunology Letters, 2002, 82, 111-121.	1.1	17
24	The role of cytokines in the epithelial cancer microenvironment. Seminars in Cancer Biology, 2002, 12, 113-120.	4.3	145
25	Tumor-associated macrophages in breast cancer. Journal of Mammary Gland Biology and Neoplasia, 2002, 7, 177-189.	1.0	330
26	Progression of mouse mammary tumors: MCP-1-TNF? cross-regulatory pathway and clonal expression of promalignancy and antimalignancy factors. International Journal of Cancer, 2003, 106, 879-886.	2.3	62
27	Natural mechanisms protecting against cancer. Immunology Letters, 2003, 90, 103-122.	1.1	181
28	Polymorphisms in tumour necrosis factor (TNF) are associated with risk of bladder cancer and grade of tumour at presentation. British Journal of Cancer, 2003, 89, 1096-1101.	2.9	45
29	Tumour necrosis factor $\hat{l}\pm$: a potential target for the therapy of solid tumours. Lancet Oncology, The, 2003, 4, 565-573.	5.1	343
30	Vascularity, Angiogenesis and Angiogenic Factors in Leukemias and Myelodysplastic Syndromes. Leukemia and Lymphoma, 2003, 44, 213-222.	0.6	40
31	Macrophages From Cancer Patients: Analysis of TRAIL, TRAIL Receptors, and Colon Tumor Cell Apoptosis. Journal of the National Cancer Institute, 2003, 95, 611-621.	3.0	51
32	Effects of introduction of dThdPase cDNA on sensitivity to 5'-deoxy-5-fluorouridine and tumor angiogenesis. International Journal of Oncology, 2003, 22, 835.	1.4	2
33	A Phase II Study of Etanercept (Enbrel), a Tumor Necrosis Factor \hat{l}_{\pm} Inhibitor in Patients with Metastatic Breast Cancer. Clinical Cancer Research, 2004, 10, 6528-6534.	3.2	180
34	Bone marrow microvascular density and angiogenic growth factors in multiple myeloma. Clinical Chemistry and Laboratory Medicine, 2004, 42, 1122-6.	1.4	35
35	Obesity, adipocytokines, and insulin resistance in breast cancer. Obesity Reviews, 2004, 5, 153-165.	3.1	415
36	Tumour-educated macrophages promote tumour progression and metastasis. Nature Reviews Cancer, 2004, 4, 71-78.	12.8	2,971

#	Article	IF	CITATIONS
37	Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer. British Journal of Cancer, 2004, 90, 2338-2343.	2.9	42
38	Immune activation and chronic inflammation as the cause of malignancy in oral lichen planus: is there any evidence?. Oral Oncology, 2004, 40, 120-130.	0.8	181
39	Role of tumour necrosis factor gene polymorphisms (-308 and -238) in breast cancer susceptibility and severity. Breast Cancer Research, 2004, 6, R395-400.	2.2	65
40	Tumor necrosis factor-? in the pathogenesis and treatment of cancer. Current Opinion in Pharmacology, 2004, 4, 314-320.	1.7	123
41	$TNFl^{\pm}_{\pm}$ played a role in induction of Akt and MAPK signals in ameloblastoma. Oral Oncology, 2005, 41, 375-382.	0.8	27
42	Serum Evaluation of Angiogenic Cytokines Basic Fibroblast Growth Factor, Hepatocyte Growth Factor and TNF-ALPHA in Patients with Myelodysplastic Syndromes: Correlation with Bone Marrow Microvascular Density. International Journal of Immunopathology and Pharmacology, 2005, 18, 287-295.	1.0	33
43	Soluble Mediators of Inflammation During Tumor Development. Advances in Cancer Research, 2005, 93, 159-187.	1.9	94
44	Breast Cancer Progression: A "Vicious Cycle―of Pro-Malignancy Activities is Mediated by Inflammatory Cells, Chemokines and Cytokines. , 2005, , 189-217.		3
45	Decreased Circulating Levels of Tumor Necrosis Factor-α in Postmenopausal Women during Consumption of Soy-Containing Isoflavones. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 3956-3962.	1.8	83
46	Thymidine phosphorylase expression in tumour cells and tumour response to capecitabine plus docetaxel chemotherapy in non-small cell lung cancer. Journal of Clinical Pathology, 2005, 58, 650-654.	1.0	22
47	Study of Etanercept, a Tumor Necrosis Factor-Alpha Inhibitor, in Recurrent Ovarian Cancer. Journal of Clinical Oncology, 2005, 23, 5950-5959.	0.8	146
48	The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer. Molecular Cancer Therapeutics, 2005, 4, 1004-1012.	1.9	145
49	Estradiol and medroxyprogesterone acetate regulated genes in T47D breast cancer cells. Molecular and Cellular Endocrinology, 2005, 235, 39-50.	1.6	11
50	Inflammation, a Key Event in Cancer Development. Molecular Cancer Research, 2006, 4, 221-233.	1.5	913
51	Association of TNF- \hat{l}_{\pm} polymorphism with susceptibility to and severity of non-small cell lung cancer. Lung Cancer, 2006, 52, 15-20.	0.9	93
52	Tumour necrosis factor-α as a tumour promoter. European Journal of Cancer, 2006, 42, 745-750.	1.3	458
53	Therapeutic potential of cytokine and chemokine antagonists in cancer therapy. European Journal of Cancer, 2006, 42, 793-802.	1.3	98
54	Macrophage-Targeted Photosensitizer Conjugate Delivered by Intratumoral Injection. Molecular Pharmaceutics, 2006, 3, 654-664.	2.3	20

#	ARTICLE	IF	CITATIONS
56	Tumour–host interactions: implications for developing anti-cancer therapies. Expert Reviews in Molecular Medicine, 2006, 8, 1-32.	1.6	13
57	Immunoediting of Cancers May Lead to Epithelial to Mesenchymal Transition. Journal of Immunology, 2006, 177, 1526-1533.	0.4	116
58	Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. Journal of Leukocyte Biology, 2006, 80, 1183-1196.	1.5	287
60	Neoadjuvant Docetaxel and Capecitabine and the Use of Thymidine Phosphorylase as a Predictive Biomarker in Breast Cancer. Clinical Cancer Research, 2007, 13, 4092-4097.	3.2	17
61	Macrophages and the hypoxic tumour microenvironment. Frontiers in Bioscience - Landmark, 2007, 12, 4298.	3.0	63
62	Modification of the tumor microenvironment to enhance immunity. Frontiers in Bioscience - Landmark, 2007, 12, 3576.	3.0	43
63	TNF alpha promoter polymorphisms analysis in benign and malignant breast lesions. Experimental and Molecular Pathology, 2007, 83, 54-58.	0.9	23
64	Potent induction of TNF-α during interaction of immune effectors with oral tumors as a potential mechanism for the loss of NK cell viability and function. Apoptosis: an International Journal on Programmed Cell Death, 2007, 12, 2063-2075.	2.2	11
65	Genetic variation in tumor necrosis factor and lymphotoxin-alpha (TNF–LTA) and breast cancer risk. Human Genetics, 2007, 121, 483-490.	1.8	62
66	Inflammation: its role and interplay in the development of cancer, with special focus on gynecological malignancies. International Journal of Gynecological Cancer, 2008, 18, 591-599.	1.2	68
67	Overexpression of TNFâ€Î± and TNFRII in invasive micropapillary carcinoma of the breast: clinicopathological correlations. Histopathology, 2008, 53, 381-388.	1.6	39
68	TNF-alpha-induced metastasis gene changes in MCF-7 cells. Journal of Nanjing Medical University, 2008, 22, 366-371.	0.1	3
69	Immune Consequences of Protracted Host-Tumor Interactions in a Transgenic Mouse Model of Mammary Carcinoma. Cancer Investigation, 2008, 26, 237-249.	0.6	8
70	Linking anemia to inflammation and cancer: The crucial role of TNFα. Biochemical Pharmacology, 2009, 77, 1572-1579.	2.0	57
71	The dual role of thymidine phosphorylase in cancer development and chemotherapy. Medicinal Research Reviews, 2009, 29, 903-953.	5.0	166
72	Association of single nucleotide polymorphisms (SNPs) in TNF-LTA locus with breast cancer risk in Indian population. Breast Cancer Research and Treatment, 2009, 114, 347-355.	1.1	54
73	How the study of Helicobacter infection can contribute to the understanding of carcinoma development. Clinical Microbiology and Infection, 2009, 15, 813-822.	2.8	6
74	Clinical significance of measuring levels of tumor necrosis factor-alpha and soluble interleukin-2 receptor in nasopharyngeal carcinoma. Acta Oto-Laryngologica, 2009, 129, 1519-1523.	0.3	17

#	Article	IF	CITATIONS
75	Gene expression of the invasive phenotype of TNF- \hat{l}_{\pm} -treated MCF-7 cells. Biomedicine and Pharmacotherapy, 2009, 63, 421-428.	2.5	45
76	Le facteur deÂnécrose tumorale: deÂlaÂbiologie ÃÂlaÂthérapie oncologique. Hematologie, 2009, 15, 291-304	ł.o.o	3
77	Significance of Serum Tumor Necrosis Factor-Alpha and its Combination with Her-2 Codon 655 Polymorphism in the Diagnosis and Prognosis of Breast Cancer. International Journal of Biological Markers, 2010, 25, 126-135.	0.7	21
79	Polymorphisms in <i>TNF</i> and <i>HSPâ€₹0</i> show a significant association with gastric cancer and duodenal ulcer. International Journal of Cancer, 2010, 126, 1861-1868.	2.3	56
80	Angiopoietin-2 Regulates Gene Expression in TIE2-Expressing Monocytes and Augments Their Inherent Proangiogenic Functions. Cancer Research, 2010, 70, 5270-5280.	0.4	299
81	Tissue Factor–Factor VIIa complex induces cytokine expression in coronary artery smooth muscle cells. Atherosclerosis, 2010, 212, 466-471.	0.4	27
82	Inflammation in Carcinogenesis. , 2010, , 401-415.		2
83	Inflammatory mediators in breast cancer: Coordinated expression of TNFα & L-1β with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition. BMC Cancer, 2011, 11, 130.	1.1	229
84	Choosing between Targeted Therapies for Rheumatoid Arthritis Patients: The Oncology Perspective. Current Rheumatology Reviews, 2011, 7, 70-76.	0.4	0
85	Tumour necrosis factor alpha -308G/A polymorphism and risk of the four most frequent cancers: a meta-analysis. International Journal of Immunogenetics, 2011, 38, 311-320.	0.8	26
86	Role of ethnic variations in TNF- $\hat{l}\pm$ and TNF- \hat{l}^2 polymorphisms and risk of breast cancer in India. Breast Cancer Research and Treatment, 2011, 126, 739-747.	1.1	38
87	TNFRSF1B +676 T>G polymorphism predicts survival of non-Small cell lung cancer patients treated with chemoradiotherapy. BMC Cancer, 2011, 11, 447.	1.1	24
89	The Interface between Inflammation and Coagulation in Cardiovascular Disease. International Journal of Inflammation, 2012, 2012, 1-8.	0.9	34
90	Macrophage-Mediated Lymphangiogenesis: The Emerging Role of Macrophages as Lymphatic Endothelial Progenitors. Cancers, 2012, 4, 618-657.	1.7	108
91	Molecular subtype is determinant on inflammatory status and immunological profile from invasive breast cancer patients. Cancer Immunology, Immunotherapy, 2012, 61, 2193-2201.	2.0	49
92	Tristetraprolin: Roles in cancer and senescence. Ageing Research Reviews, 2012, 11, 473-484.	5.0	58
93	Antioxidant and Immunity Activities of Fufang Kushen Injection Liquid. Molecules, 2012, 17, 6481-6490.	1.7	23
94	Effect of Tumour Necrosis Factor-Alpha on Estrogen Metabolic Pathways in Breast Cancer Cells. Journal of Cancer, 2012, 3, 310-321.	1.2	37

#	Article	IF	CITATIONS
95	The Tumor-Promoting Flow of Cells Into, Within and Out of the Tumor Site: Regulation by the Inflammatory Axis of TNF \hat{l} ± and Chemokines. Cancer Microenvironment, 2012, 5, 151-164.	3.1	55
96	Immunological effects of Taxol and Adryamicin in breast cancer patients. Cancer Immunology, Immunotherapy, 2012, 61, 481-488.	2.0	31
97	Differential oxidative status and immune characterization of the early and advanced stages of human breast cancer. Breast Cancer Research and Treatment, 2012, 133, 881-888.	1.1	92
98	Inflammatory and microenvironmental factors involved in breast cancer progression. Archives of Pharmacal Research, 2013, 36, 1419-1431.	2.7	78
99	Unincluded subjects need to be included for concerning the real association between TNFaâ^'308 G/A polymorphism and cancer susceptibility. Breast Cancer Research and Treatment, 2013, 137, 645-646.	1.1	0
100	Inflammatory Factors of the Tumor Microenvironment Induce Plasticity in Nontransformed Breast Epithelial Cells: EMT, Invasion, and Collapse of Normally Organized Breast Textures. Neoplasia, 2013, 15, 1330-IN5.	2.3	55
101	Origins and Actions of Tumor Necrosis Factor \hat{l}_{\pm} in Postmenopausal Breast Cancer. Journal of Interferon and Cytokine Research, 2013, 33, 335-345.	0.5	14
102	Involvement of early growth response factors in TNFα-induced aromatase expression in breast adipose. Breast Cancer Research and Treatment, 2013, 138, 193-203.	1.1	13
103	Magnetic Resonance in the Detection of Breast Cancers of Different Histological Types. Magnetic Resonance Insights, 2013, 6, MRI.S10640.	2.5	10
104	DEPLETION OF TUMOR-ASSOCIATED MACROPHAGES WITH CLODRONATE-LOADED PLGA NANOPARTICLES. Nano LIFE, 2013, 03, 1343005.	0.6	1
105	Obesity and breast cancer: role of inflammation and aromatase. Journal of Molecular Endocrinology, 2013, 51, T51-T59.	1.1	75
106	Association of TNF-α, TNFRSF1A and TNFRSF1B Gene Polymorphisms with the Risk of Sporadic Breast Cancer in Northeast Chinese Han Women. PLoS ONE, 2014, 9, e101138.	1.1	30
107	Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis. Frontiers in Physiology, 2014, 5, 75.	1.3	463
108	The Utility of Pro-inflammatory Cytokines-TNF Alpha and CRP as Indicators of Response to Chemotherapy in Patients with Breast Carcinoma. Journal of Molecular Biomarkers & Diagnosis, 2014, 05, .	0.4	1
109	Tumor necrosis factor-alpha gene â^308G > A polymorphism alters the risk of hepatocellular carcinoma in a Han Chinese population. Diagnostic Pathology, 2014, 9, 199.	0.9	9
110	The Role of Inflammation in Gastric Cancer. Advances in Experimental Medicine and Biology, 2014, 816, 235-257.	0.8	15
111	Thymidine Phosphorylase Regulates the Expression of CXCL10 in Rheumatoid Arthritis Fibroblastâ€ike Synoviocytes. Arthritis and Rheumatology, 2014, 66, 560-568.	2.9	25
112	Association between the tumor necrosis factor alpha gene â^308G> A polymorphism and the risk of breast cancer: a meta-analysis. Tumor Biology, 2014, 35, 12091-12098.	0.8	12

#	Article	IF	CITATIONS
113	Estradiol regulates Tumor Necrosis Factor- $\hat{l}\pm$ expression and secretion in Estrogen Receptor positive breast cancer cells. Molecular and Cellular Endocrinology, 2014, 394, 21-28.	1.6	18
114	Triterpenes from the Protium heptaphyllum resin – chemical composition and cytotoxicity. Revista Brasileira De Farmacognosia, 2014, 24, 399-407.	0.6	17
115	Tumour Necrosis Factor-α Gene Polymorphism Is Associated with Metastasis in Patients with Triple Negative Breast Cancer. Scientific Reports, 2015, 5, 10244.	1.6	23
116	CD11b deficiency suppresses intestinal tumor growth by reducing myeloid cell recruitment. Scientific Reports, 2015, 5, 15948.	1.6	40
117	Regulation of the inflammatory profile of stromal cells in human breast cancer: prominent roles for TNF-α and the NF-ÎB pathway. Stem Cell Research and Therapy, 2015, 6, 87.	2.4	108
118	The Role of Cytokines in Breast Cancer Development and Progression. Journal of Interferon and Cytokine Research, 2015, 35, 1-16.	0.5	387
119	Expression of COX-2, IL- $1\hat{1}^2$, TNF- $\hat{1}^{\pm}$ and IL-4 in epithelium of serrated adenoma, adenoma and hyperplastic polyp. Archives of Medical Science, 2016, 1, 172-178.	0.4	19
120	Susceptibility Risk Alleles of -238G/A, -308G/A and -1031T/C Promoter Polymorphisms of TNF-α Gene to Uterine Leiomyomas. Recent Advances in DNA & Gene Sequences, 2016, 9, 65-71.	0.7	3
121	Cytokine Regulation of Metastasis and Tumorigenicity. Advances in Cancer Research, 2016, 132, 265-367.	1.9	86
122	Inflammation: the Common Link in Brain Pathologies. , 2016, , .		1
123	Tumor necrosis factor-α (TNF-α)-308G/A promoter polymorphism in colorectal cancer in ethnic Kashmiri population â€" A case control study in a detailed perspective. Meta Gene, 2016, 9, 128-136.	0.3	30
125	The effect of resistance training on markers of immune function and inflammation in previously sedentary women recovering from breast cancer: a randomized controlled trial. Breast Cancer Research and Treatment, 2016, 155, 471-482.	1.1	82
126	Cancer-Induced Fatigue and Cachexia. , 2016, , 147-174.		0
127	Tumor-associated macrophages: Potential therapeutic targets for anti-cancer therapy. Advanced Drug Delivery Reviews, 2016, 99, 180-185.	6.6	469
128	Preventive effect of berberine against DMBA-induced breast cancer in female Sprague Dawley rats. Biomedicine and Pharmacotherapy, 2017, 92, 207-214.	2.5	61
129	Tumor necrosis factor alpha-238G/A polymorphism and risk of breast cancer. Medicine (United States), 2017, 96, e7442.	0.4	12
130	Translational Significance for Tumor Metastasis of Tumor-Associated Macrophages and Epithelial–Mesenchymal Transition. Frontiers in Immunology, 2017, 8, 1106.	2.2	69
131	Tumor-fibroblast interactions stimulate tumor vascularization by enhancing cytokine-driven production of MMP9 by tumor cells. Oncotarget, 2017, 8, 35592-35608.	0.8	42

#	Article	IF	CITATIONS
132	Pre-operative progesterone benefits operable breast cancer patients by modulating surgical stress. Breast Cancer Research and Treatment, 2018, 170, 431-438.	1.1	9
133	A Fibroblast Growth Factor Antagonist Peptide Inhibits Breast Cancer in BALB/c Mice. Open Life Sciences, 2018, 13, 348-354.	0.6	6
134	Macrophage Polarization in Chronic Inflammatory Diseases: Killers or Builders?. Journal of Immunology Research, 2018, 2018, 1-25.	0.9	325
135	The inhibitory effects of plumbagin on the NF-Ò>B pathway and CCL2 release in racially different triple-negative breast cancer cells. PLoS ONE, 2018, 13, e0201116.	1.1	22
136	Tumor necrosis factor-alpha and tumor necrosis factor beta polymorphisms and risk of breast cancer: Review. Gene Reports, 2018, 12, 317-323.	0.4	0
137	Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy. Frontiers in Immunology, 2018, 9, 527.	2.2	297
138	TGF- \hat{l}^2 signaling promotes tumor vasculature by enhancing the pericyte-endothelium association. BMC Cancer, 2018, 18, 670.	1.1	58
139	Elevated Levels of TNF-α and Decreased Levels of CD68-Positive Macrophages in Primary Tumor Tissues Are Unfavorable for the Survival of Patients With Nasopharyngeal Carcinoma. Technology in Cancer Research and Treatment, 2019, 18, 153303381987480.	0.8	14
140	M2 polarization of macrophages by Oncostatin M in hypoxic tumor microenvironment is mediated by mTORC2 and promotes tumor growth and metastasis. Cytokine, 2019, 118, 130-143.	1.4	51
141	The dual role of tumor necrosis factor-alpha (TNF- $\hat{l}\pm$) in breast cancer: molecular insights and therapeutic approaches. Cellular Oncology (Dordrecht), 2020, 43, 1-18.	2.1	240
142	Role of Tumor-Associated Myeloid Cells in Breast Cancer. Cells, 2020, 9, 1785.	1.8	56
143	Polymorphisms in the Tumor Necrosis Factor Genes Are Associated with Breast Cancer in the Moroccan Population. Genetic Testing and Molecular Biomarkers, 2020, 24, 592-599.	0.3	1
144	Tumor Necrosis Factor \hat{l}_{\pm} Blockade: An Opportunity to Tackle Breast Cancer. Frontiers in Oncology, 2020, 10, 584.	1.3	96
145	Pupae protein extracts exert anticancer effects by downregulating the expression of IL-6, IL- $\hat{1}^2$ and TNF- $\hat{1}^\pm$ through biomolecular changes in human breast cancer cells. Biomedicine and Pharmacotherapy, 2020, 128, 110278.	2.5	18
146	Oxidative Stress and Inflammation Can Fuel Cancer. , 2020, , 229-258.		13
147	Importance of TNF-alpha and its alterations in the development of cancers. Cytokine, 2020, 130, 155066.	1.4	40
148	Tissue-resident memory T cells in breast cancer control and immunotherapy responses. Nature Reviews Clinical Oncology, 2020, 17, 341-348.	12.5	159
149	Tumor Immunology and Tumor Evolution: Intertwined Histories. Immunity, 2020, 52, 55-81.	6.6	357

#	ARTICLE	IF	CITATIONS
150	The Interplay between Oxidative Stress, Inflammation and Angiogenesis in Bladder Cancer Development. International Journal of Molecular Sciences, 2021, 22, 4483.	1.8	53
151	The Cancer Cell Dissemination Machinery as an Immunosuppressive Niche: A New Obstacle Towards the Era of Cancer Immunotherapy. Frontiers in Immunology, 2021, 12, 654877.	2.2	19
152	Upregulation of Bax, TNF- $\hat{l}\pm$ and down-regulation of Bcl-2 in liver cancer cells treated with HL-7 and HL-10 peptides. Biologia (Poland), 2021, 76, 2735-2743.	0.8	3
153	Peripheral blood immune markers in breast cancer: Differences in regulatory T cell abundance are related to clinical parameters. Clinical Immunology, 2021, 232, 108847.	1.4	3
154	Lung Cancer Susceptibility and Risk Assessment Models., 0,, 33-60.		1
155	Classical and alternative activation of macrophages: different pathways of macrophage-mediated tumor promotion., 2008,, 139-156.		1
156	Angiogenesis in Endometriosis., 2001,, 245-270.		1
157	Tumor Necrosis Factor and Cancer. , 2007, , 71-89.		7
158	Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood, 2000, 96, 2240-2245.	0.6	23
159	Dysregulation of Cell Polarity Proteins Synergize with Oncogenes or the Microenvironment to Induce Invasive Behavior in Epithelial Cells. PLoS ONE, 2012, 7, e34343.	1.1	30
160	Macrophage Colony-Stimulating Factor Augments Tie2-Expressing Monocyte Differentiation, Angiogenic Function, and Recruitment in a Mouse Model of Breast Cancer. PLoS ONE, 2014, 9, e98623.	1.1	74
161	TRIM59 loss in M2 macrophages promotes melanoma migration and invasion by upregulating MMP-9 and Madcam1. Aging, 2019, 11, 8623-8641.	1.4	24
162	Microenvironmental networks promote tumor heterogeneity and enrich for metastatic cancer stem-like cells in Luminal-A breast tumor cells. Oncotarget, 2016, 7, 81123-81143.	0.8	23
163	The association between obesity related adipokines and risk of breast cancer: a meta-analysis. Oncotarget, 2017, 8, 75389-75399.	0.8	79
164	Tumor p38MAPK signaling enhances breast carcinoma vascularization and growth by promoting expression and deposition of pro-tumorigenic factors. Oncotarget, 2017, 8, 61969-61981.	0.8	25
165	Breast cancer associated a2 isoform vacuolar ATPase immunomodulates neutrophils: potential role in tumor progression. Oncotarget, 2015, 6, 33033-33045.	0.8	26
166	Genetic Polymorphism in TNF-α-308 G/A and TNF-β +252 A/G, as Prognostic Biomarker in Breast Cancer Patients among Indian Population. Asian Pacific Journal of Cancer Prevention, 2020, 21, 301-308.	0.5	6
167	Emerging candidates in breast cancer stem cell maintenance, therapy resistance and relapse. Journal of Carcinogenesis, 2011, 10, 36.	2.5	7

#	ARTICLE	IF	CITATIONS
168	Prognostic Value of Proinflammatory Cytokines in Breast Cancer. Journal of Biomolecular Research $\&$ Therapeutics, 2013, 01, .	0.2	4
169	Role of platelets and breast cancer stem cells in metastasis. World Journal of Stem Cells, 2020, 12, 1237-1254.	1.3	18
170	Novel Insights Into the Role of Inflammation in Promoting Breast Cancer Development. , 0, , .		1
171	Diagnostic and Prognostic Importance of the Neutrophil Lymphocyte Ratio in Breast Cancer. Asian Pacific Journal of Cancer Prevention, 2015, 15, 10363-10366.	0.5	22
172	The Chronically Inflamed Microenvironment and Cancer Stem Cells. , 2009, , 235-250.		0
173	Cytokines and Breast Cancer. , 2011, , 189-202.		0
174	Oxidative Stress in Breast Cancer. , 2014, , 609-641.		0
175	Clinical significance of angiogenic factors in breast cancer. , 1998, , 249-263.		0
176	Brain Tumors and Inflammation. , 2016, , 253-280.		0
177	CYTOKINES GENETIC POLYMORPHISM: THE PAST AND THE FUTURE. Russian Journal of Infection and Immunity, 2016, 6, 103-108.	0.2	3
178	Association of XRCC1, HMMR genes with breast cancer in the Kyrgyz ethnic group. Malignant Tumours, 2019, 8, 45-49.	0.1	0
179	Molecular mechanism of gossypol mediating CCL2 and ILâ€'8 attenuation in tripleâ€'negative breast cancer cells. Molecular Medicine Reports, 2020, 22, 1213-1226.	1.1	5
180	Sanguinarine Inhibition of TNF-α-Induced CCL2, IKBKE/NF-κB/ERK1/2 Signaling Pathway, and Cell Migration in Human Triple-Negative Breast Cancer Cells. International Journal of Molecular Sciences, 2022, 23, 8329.	1.8	8
182	Inflammatory Cytokine: An Attractive Target for Cancer Treatment. Biomedicines, 2022, 10, 2116.	1.4	19
183	Transcriptomic Profiling of Breast Cancer Cells Induced by Tumor-Associated Macrophages Generates a Robust Prognostic Gene Signature. Cancers, 2022, 14, 5364.	1.7	2
184	Macrophages as a Potential Immunotherapeutic Target in Solid Cancers. Vaccines, 2023, 11, 55.	2.1	10
185	Asiaticoside Increases Caspase-9 Activity in MCF-7 Cells and Inhibits TNF-α and IL-6 Expression in Nude Mouse Xenografts via the NF-κB Pathway. Molecules, 2023, 28, 2101.	1.7	1
186	Metagenomics Analysis of Breast Microbiome Highlights the Abundance of Rothia Genus in Tumor Tissues. Journal of Personalized Medicine, 2023, 13, 450.	1.1	6

Article IF Citations